OS Therapies appoints Rubenstein PR to lead global communications for its cancer immunotherapy advances
Alpha Vantage · Pluang · · AI-summarised by FinFlash
OS Therapies, a clinical-stage oncology company focusing on gene-edited cancer immunotherapies, has appointed Rubenstein Public Relations as its Agency of Record for global communications. This partnership aims to bolster the company's corporate messaging and brand presence as it advances its lead immunotherapy, OST-HER2, towards regulatory approvals in the US and UK in 2026 for osteosarcoma and other solid tumors. The announcement was accompanied by Health-sector market data, showing a mixed performance for US stocks on Pluang.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.